These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1145 related articles for article (PubMed ID: 29704644)

  • 21. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
    Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
    Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Essential oils from Inula japonica and Angelicae dahuricae enhance sensitivity of MCF-7/ADR breast cancer cells to doxorubicin via multiple mechanisms.
    Wu M; Li T; Chen L; Peng S; Liao W; Bai R; Zhao X; Yang H; Wu C; Zeng H; Liu Y
    J Ethnopharmacol; 2016 Mar; 180():18-27. PubMed ID: 26795076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
    Tiash S; Chowdhury EH
    J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells.
    Chaisit T; Siripong P; Jianmongkol S
    Eur J Pharmacol; 2017 Jan; 795():50-57. PubMed ID: 27916559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy.
    Zhang H; Yu J; Ma L; Zhao Y; Xu S; Shi J; Qian K; Gu M; Tan H; Xu L; Liu Y; Mu C; Xiong Y
    Int J Pharm; 2022 Aug; 624():121931. PubMed ID: 35750278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells.
    Li Y; Zhai Z; Li H; Wang X; Huang Y; Su X
    Chem Biol Interact; 2019 May; 305():98-104. PubMed ID: 30929998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
    Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
    Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by beta-elemene].
    Hu J; Jin W; Yang PM
    Zhonghua Zhong Liu Za Zhi; 2004 May; 26(5):268-70. PubMed ID: 15312359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
    Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
    Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
    Zaja R; Caminada D; Loncar J; Fent K; Smital T
    Toxicol Appl Pharmacol; 2008 Mar; 227(2):207-18. PubMed ID: 18076962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells.
    Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A
    Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.